Article Information
- Received April 12, 2024
- Revision received May 17, 2024
- Accepted May 28, 2024
- Published online June 24, 2024.
Author Information
- Trina Basu1,
- Pantelis Antonoudiou1,
- Grant L. Weiss1,
- Emanuel M. Coleman1,
- Julian David2,
- Daniel Friedman3,
- Juliana Laze3,
- Misty M. Strain2,
- Orrin Devinsky3,
- Carie R. Boychuk2 and
- Jamie Maguire1
- 1Tufts University School of Medicine, Boston, Massachusetts 02111
- 2University of Missouri, Columbia, Missouri 65211
- 3New York University Langone Medical Center Comprehensive Epilepsy Center, New York, New York 10016
- Correspondence should be addressed to Jamie Maguire at jamie.maguire{at}tufts.edu.
Author contributions
Author contributions: T.B., P.A., G.L.W., C.R.B., and J.M. designed research; T.B., E.M.C., J.D., M.M.S., C.R.B., and J.M. performed research; D.F., J.L., and O.D. contributed unpublished reagents/analytic tools; T.B., P.A., G.L.W., E.M.C., J.D., M.M.S., C.R.B., and J.M. analyzed data; T.B., P.A., and J.M. wrote the paper.
Disclosures
J.M. serves on the Scientific Advisory Board for SAGE Therapeutics and has a sponsored research agreement with SAGE Therapeutics for experiments unrelated to the current study. O.D. receives equity and compensation from the following companies (all of which are unrelated to the current study): Tilray, Receptor Life Sciences, Qstate Biosciences, Hitch Biosciences, Tevard Biosciences, Regel Biosciences, Script Biosciences, Empatica, SilverSpike, and California Cannabis Enterprises (CCE). O.D. receives consulting fees from the following (all of which are unrelated to the current study): Zogenix, Ultragenyx, BridgeBio Pharma, and Marinus Pharmaceuticals. O.D. has patents for the use of cannabidiol in treating neurological disorders which are owned by GW Pharmaceuticals; O.D. has waived all financial interests in this partnership. D.F. receives salary support for consulting and clinical trial related activities from The Epilepsy Study Consortium.
Unrelated to the current study, The Epilepsy Study Consortium received payments for research services provided by D.F. from the following: Alterity, Baergic Bio, Biogen, BioXcell, Cerevel Therapeutics, Cerebral, Janssen Pharmaceuticals, Lundbeck, Neurocrine, SK Life Science, and Xenon. D.F. serves as a consultant for Neurelis Pharmaceuticals and Receptor Life Sciences. D.F. holds equity interests in Neuroview Technology and receives royalty income from Oxford University Press. All other authors declare no competing financial interests.
T.B., P.A., G.L.W., and J.M. are supported by funding from the National Institutes of Health under award numbers F31AA028410, R01AA026256, R01NS105628, R01NS102937, R01MH128235, and P50MH122379. O.D. is supported by funding from National Institute of Neurological Disorders and Stroke (NINDS; 18-A0-00-1000473, 16-A0-00-006058/107311), Centers for Disease Control and Prevention (CDC; 26 B 89011), National Science Foundation (NSF; 26 D 70200), and GW Pharmaceuticals (C19-01030-1012157/116548). D.F. is supported by funding from NINDS (R01 NS109367, R01 NS233102, R01NS123928, 1U44NS121562), NSF (A20 0089 S001), and CDC (6U48DP006396). Human blood samples used in this study were provided by the North American SUDEP Registry (NASR) and funded by Finding a Cure for Epilepsy and Seizures (FACES).
Funding
HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
R01NS105628; R01NS102937
Other Version
- You are viewing the most recent version of this article.
- previous version (June 24, 2024).
Article usage
In this issue
